Outlook Therapeutics

-$0.02 (-1.47%) As of 5:08 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.

CEO
C. Russell Trenary
Employees
9
Headquarters
Iselin, New Jersey
Founded
2010

OTLK Key Statistics

Market cap
227.07M
Price-Earnings ratio
—
Dividend yield
—
Average volume
493.71K
High today
$1.05
Low today
$1.00
Open price
$1.02
Volume
206.51K
52 Week high
$3.27
52 Week low
$0.6839

OTLK Earnings

-$0.12
-$0.08
-$0.04
$0.00
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
— per share
Actual
Expected Aug 12, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure